Patents by Inventor Anne Camille La Flamme

Anne Camille La Flamme has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF DEMYELINATING DISEASES
    Publication number: 20230096920
    Abstract: The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
    Type: Application
    Filed: September 30, 2022
    Publication date: March 30, 2023
    Inventors: Thomas Edward Prisinzano, Bronwyn Maree Kivell, Anne Camille La Flamme
  • Treatment of demyelinating diseases
    Patent number: 11324742
    Abstract: The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
    Type: Grant
    Filed: July 23, 2020
    Date of Patent: May 10, 2022
    Assignees: Victoria Link Ltd., University of Kansas
    Inventors: Thomas Edward Prisinzano, Bronwyn Maree Kivell, Anne Camille La Flamme
  • TREATMENT OF DEMYELINATING DISEASES
    Publication number: 20210069179
    Abstract: The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
    Type: Application
    Filed: July 23, 2020
    Publication date: March 11, 2021
    Inventors: Thomas Edward Prisinzanno, Bronwyn Maree Kivell, Anne Camille La Flamme
  • TREATMENT OF DEMYELINATING DISEASES
    Publication number: 20210023074
    Abstract: The present invention relates generally to methods of using nalmefene for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalmefene for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalmefene for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
    Type: Application
    Filed: March 7, 2019
    Publication date: January 28, 2021
    Inventors: Bronwyn Maree Kivell, Anne Camille La Flamme, Thomas Edward Prisinzano
  • TREATMENT OF DEMYELINATING DISEASES
    Publication number: 20210015813
    Abstract: The present invention relates generally to methods of using nalfurafine for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing multiple sclerosis (MS). Also disclosed is nalfurafine for use in treating and/or preventing MS as well as pharmaceutical compositions and unit dosage forms comprising nalfurafine for use for treating and/or preventing demyelinating disease in a subject, and in particular for treating and/or preventing MS.
    Type: Application
    Filed: March 7, 2019
    Publication date: January 21, 2021
    Inventors: Bronwyn Maree Kivell, Anne Camille La Flamme, Thomas Edward Prisinzano
  • METHODS AND COMPOSITIONS FOR TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20130190299
    Abstract: Methods and formulations for the treatment of multiple sclerosis with drugs with affinity for both serotonergic 5-HT2 and dopaminergic receptors such as the D2 receptor are herein disclosed. According to one embodiment, a method includes delivering a therapeutic dosage of drugs with affinity for both serotonergic 5-HT2 and dopaminergic receptors such as the D2 receptors to a subject exhibiting symptoms of multiple sclerosis to alleviate the symptoms.
    Type: Application
    Filed: June 28, 2011
    Publication date: July 25, 2013
    Applicant: Victoria Link Ltd.
    Inventors: Anne Camille La Flamme, Bronwen Jane Connor, David O'Sullivan